Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK), a leading innovation-driven pharmaceutical company in China, and Guangzhou Lupeng Pharmaceutical Co., Ltd. (Lupeng Pharma), which specializes in treatments for malignant tumors and autoimmune diseases, have announced a licensing agreement for LP-168, a small molecule Bruton’s tyrosine kinase inhibitor (BTKi) developed independently by Lupeng Pharma.
Under the terms of the agreement, Hansoh Pharma secures an exclusive license to develop and commercialize LP-168 for all non-tumor indications across China, including Hong Kong, Macau, and Taiwan. Hansoh Pharma will handle the research and development (R&D), regulatory approval, manufacturing, and commercialization of LP-168 in these indications. The agreement includes an upfront payment and potential milestone payments totaling up to RMB 729 million, along with tiered royalties on future sales.
LP-168 is a small molecule BTKi currently in various stages of clinical trials in China, including a Phase II pivotal trial for tumors.
Eliza Sun, Executive Director of the Board at Hansoh Pharma, stated, “Hansoh Pharma is actively pursuing high-value, potential blockbuster products in the non-tumor sector. This collaboration with Lupeng Pharma will expand our pipeline for autoimmune disorder treatments and offer more options for patients with chronic autoimmune conditions.”
Dr. Fenlai Tan, Chairman, CEO, and CMO of Lupeng Pharma, remarked, “LP-168 represents a next-generation BTKi with a strong safety profile and unique advantages. We believe that Hansoh Pharma’s extensive experience and resources will expedite the clinical development and commercialization of LP-168 for autoimmune diseases, significantly impacting treatment options both in China and globally.”
Hansoh Pharma
Hansoh Pharma is a leading pharmaceutical company in Greater China focused on innovation. The company addresses major diseases in oncology, anti-infections, CNS diseases, metabolic disorders, and autoimmune diseases. Ranked among the top 100 global pharmaceutical companies and the top 3 in China for pharmaceutical R&D, Hansoh Pharma is listed on the Stock Exchange of Hong Kong (stock code: 03692.HK). For more information, visit www.hspharm.com. Lupeng Pharmaceutical
Co-founded by Dr. Fenlai Tan and Dr. Chen Yi in Guangzhou in June 2018, Lupeng Pharmaceutical targets key molecules like BTK, Bcl-2, and Bcl-xL in hematological tumors and develops innovative drugs for cancer and autoimmune diseases. With a robust R&D pipeline, Lupeng’s core programs, Rocbrutinib (LP-168) and Lacutoclax (LP-108), have advanced to pivotal registration trials. The company continues to attract investment from notable biopharmaceutical venture capital funds and aims to become a globally competitive biopharmaceutical entity with a comprehensive R&D, manufacturing, and commercialization framework in the Greater Bay Area.
